Stockreport

MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights [Yahoo! Finance]

MBX Biosciences, Inc.  (MBX) 
PDF MBX Biosciences, Inc. Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeti [Read more]